Sayan M, Akhan SC, Meric M. Naturally occurring amino-acid substi- tutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B[J]. J Viral Hepat, 2010, 17(1):23-27. [2] Fung S, Wong F, Mazzulli T, et al . Pre-existing antiviral-resistant mutation may be associated with primary non-response to lamivudine among treatment-na?ve chronic hepatitis B patients[J]. Hepatolo- gy, 2009, 50(S4): 523A. [3] Hayashi K, Katano Y, Ishigami M, et al . Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivu- dine-resistant strains[J]. J Gastroenterol Hepatol, 2010, doi:10./ 1111/j.1440-1746.2009.06118.x [4]中华医学会传染病与寄生虫学分会、肝病学分会.病毒性肝炎防 治方案[J].中华肝脏病杂志, 2000, 8(6): 324-329. [5] Liu Y, Zhong Y, Zou Z, et al . Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/pre- core region in 507 Chinese patients with acute and chronic hepatitis B [J]. J Clin Virol, 2010, 47(3):243-247. [6]徐东平,刘妍,成军,等. 340例慢性乙型肝炎患者乙型肝炎病毒 多位点耐药相关突变分析[J].中华肝脏病杂志, 2008, 16(10): 735-738. [7] Margeridon-Thermet S, Shulman NS, Ahmed A, et al . Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor(NRTI)-treated patients and NRTI-na⒍ve patients[J]. J Infect Dis, 2009, 199(9):1275-1285. [8]徐东平,周先志.核苷(酸)类似物治疗慢性乙型肝炎耐药研究进 展[J].传染病信息, 2007, 20(2):68-70. [9] Lok AS, Zoulim F, Locarnini S, et al . Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommenda- tions for management[J]. Hepatology, 2007, 46(1):254-265. [10] Fung SK, Fontana RJ. Management of drug-resistant chronic hepati- tis B[J]. Clin Liver Dis, 2006, 10(2): 275-302. [11]徐东平.乙型肝炎病毒耐药的检测与判断[J].中华肝脏病杂志, 2009, 17(S):61-63. [12] Liu Y, Wang CM, Xu DP. Analysis of hepatitis B virus drug-resist- ant mutations for 2000 patients with chronic hepatitis B virus in China [J]. Hepatol Int, 2009, 3(1):111.